Delta-Fly Pharma, Inc. (TYO:4598)

Japan flag Japan · Delayed Price · Currency is JPY
647.00
+44.00 (7.30%)
May 30, 2025, 3:30 PM JST
6.59%
Market Cap 6.30B
Revenue (ttm) n/a
Net Income (ttm) -1.72B
Shares Out 9.73M
EPS (ttm) -195.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 883,000
Average Volume 380,855
Open 599.00
Previous Close 603.00
Day's Range 599.00 - 652.00
52-Week Range 403.00 - 765.00
Beta -0.93
RSI 74.74
Earnings Date May 15, 2025

About Delta-Fly Pharma

Delta-Fly Pharma, Inc. develops anticancer drugs. It develops DFP-10917 that is in phase III clinical trial in the United States and phase I trial in Japan for the treatment of relapsed/refractory acute myeloid leukemia; DFP-14323, which is in phase III clinical trial to treat lung cancer; DFP-17729 that is in phase I/II clinical trials for the treatment of solid cancer; DFP-11207, which has completed phase I clinical trial to treat pancreatic cancer; DFP-14927 that is in phase I for the treatment of hematologic cancer; and DFP-10825, which is ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 13
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4598
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.